Back to All Combinations

TMB-High (≥10 mut/Mb)

Intermediate Prognosis
5.00% Prevalence Level 2A Immunotherapy Biomarkers
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
Multiple
Treatment Implications

FDA-approved tumor-agnostic biomarker for pembrolizumab.

Recommended Treatments
Pembrolizumab
Treatments to Avoid

No specific contraindications noted

Study References

KEYNOTE-158

Key Statistics
5.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Can occur in MSS tumors. Check NGS for TMB score.
Information

Category: Immunotherapy Biomarkers

Evidence Level: Level 2A

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.